share_log

Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20

Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20

摩根士丹利将Amicus Therapeutics上调至增持,将目标股价提高至20美元
Benzinga ·  2023/12/19 09:09

Morgan Stanley analyst Jeffrey Hung upgrades Amicus Therapeutics (NASDAQ:FOLD) from Equal-Weight to Overweight and raises the price target from $15 to $20.

摩根士丹利分析师洪杰弗里将Amicus Therapeutics(纳斯达克股票代码:FOLD)从等权重上调至增持,并将目标股价从15美元上调至20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发